Kaya-Akyuzlu, D. Et Al. 2022. Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY , vol.95 .

Kaya-Akyuzlu, D., Ozkan-Kotiloglu, S., Bal, C., Avcioglu, G., Yalcin-Sahiner, Ş., & Sahiner, I. V., (2022). Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY , vol.95.

Kaya-Akyuzlu, DİLEK Et Al. "Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder," ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY , vol.95, 2022

Kaya-Akyuzlu, DİLEK Et Al. "Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder." ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY , vol.95, 2022

Kaya-Akyuzlu, D. Et Al. (2022) . "Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder." ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY , vol.95.

@article{article, author={DİLEK AKYÜZLÜ Et Al. }, title={Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder}, journal={ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY}, year=2022}